| Pair Name | Bufalin, Doxorubicin | ||
| Phytochemical Name | Bufalin (PubChem CID: 9547215 ) | ||
| Anticancer drug Name | Doxorubicin (PubChem CID: 31703 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Bufalin, Doxorubicin | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
| Up-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Expression | BID | hsa637 | |
| In Vitro Model | Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 |
| HLE | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_1281 | |
| Result | These results suggested that the combination of cinobufacini and doxorubicin may provide a new strategy for inhibiting the proliferation of HCC cells. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Combination of Cinobufacini and Doxorubicin Increases Apoptosis of Hepatocellular Carcinoma Cells through the Fas- and Mitochondria-Mediated Pathways. Am J Chin Med. 2017;45(7):1537-1556. doi: 10.1142/S0192415X17500835. | Click |
